alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,376–1,400 of 1,459 studies in Brain scans and imaging (page 56 of 59) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Alzheimers and Brain Tumor Detection Using Deep Learning

✓ Peer-reviewed alzhub usefulness score 28 out of 100. International Journal of Innovative Science and Research Technology 2025-05-02

The results may contribute to refining current diagnostic techniques, promoting earlier detection, and assisting in the development of advanced tools for accurate brain tumor diagnosis and treatment planning. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Application of Convolutional Neural Network Based on ResNet18 for Alzheimer Disease Classification

✓ Peer-reviewed alzhub usefulness score 28 out of 100. International Journal of Artificial Intelligence Research 2025-12-30

Alzheimer's disease is a form of progressive dementia that significantly impacts the quality of life of patients and their families. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer Detection Using Deep Learning Methods

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Journal of Intelligent Systems and Internet of Things 2025-01-01

This study proposes a deep learning-based framework to detect and classify Alzheimer's disease (AD) in the early stages using medical imaging, and specifically Magnetic Resonance Imaging (MRI). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Ophthalmic imaging and artificial intelligence in early diagnosis of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Neurology Bulletin 2025-12-16

Alzheimer disease represents a major medical and social challenge owning to the complexity of its diagnosis, especially at the preclinical stage. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

ENHANCED ALZHEIMER DISEASE DIAGNOSIS THROUGH DEEP LEARNING-BASED MRI SEGMENTATION AND CLASSIFICATION

✓ Peer-reviewed alzhub usefulness score 26 out of 100. RCHUB JOURNAL OF COMPUTATIONAL INTELLIGENCE SCIENCE AND ENGINEERING (JCISE) 2026-07-01

The accurate diagnosis tends to remain critical for the improvement of the patient outcomes in the Alzheimer’s disease (AD), where a progressive neurodegenerative disorder with the growing of the global impact. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A survey on various Alzheimer classification techniques using 3D MRI images: a challenging overview

✓ Peer-reviewed alzhub usefulness score 25 out of 100. International Journal of Information and Decision Sciences 2025-01-01

This survey presents 50 research papers focussed on various techniques in Alzheimer classification techniques using 3D MRI images, and the categorisation of the techniques is made based on the fusion-based, convolutional neural network (CNN)-based, random forest (RF)-based and support vector machine (SVM)-based approaches. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

RETRACTED: Revolutionizing medical imaging: A cutting-edge AI framework with vision transformers and perceiver IO for multi-disease diagnosis

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Computational Biology and Chemistry 2025-07-04

The integration of artificial intelligence in medical image classification has significantly advanced disease detection. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impaired cerebrovascular-cerebrospinal fluid coupling is associated with non-motor features of Lewy body disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-19

Parkinsons disease and dementia with Lewy bodies patients both demonstrated weaker global BOLD-CSF coupling compared to controls, with no detectable difference between patient groups. 4 key findings →

Participants: 39 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Deep multimodal clustering identifies biological subtypes of normal aging with divergent cognitive decline risk

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-19

Cognitively normal older adults are often regarded as a homogeneous population in preventive and disease-modifying clinical trials for dementia. 2 key findings →

Design: prospective cohort Participants: 1,136 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-27

Neuropsychiatric symptoms (NPS) are increasingly recognized as critical components of the disease progression in Alzheimers disease (AD), yet their relationship with neurodegeneration remain poorly characterized. 2 key findings →

Participants: 1,756 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Meta-analysis of glucose metabolism across Alzheimer's, Parkinson's and ALS reveals distinct patterns of cortical hypometabolism versus subcortical hypermetabolism with disease-specific spatial signatures

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-31

The purpose of this meta-analysis was to determine the common signature of dysregulated brain glucose metabolism in late-onset age-associated neurodegenerative diseases (A2NDs), including Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis. 2 key findings →

Design: meta-analysis Participants: 5,298 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Left ventricular hypertrophy, brain atrophy and cognitive decline in type 2 diabetes mellitus: Diabetes & Dementia (D2) cohort study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-02

BACKGROUNDPeople with type 2 diabetes mellitus (T2DM) are at higher risk of cerebral small vessel disease and left ventricular hypertrophy (LVH), potentially contributing to cognitive decline and dementia. 5 key findings →

Design: cohort study Participants: 62 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Dopaminergic therapy selectively amplifies hallucination susceptibility in patients with Parkinson's disease with cortico-striatal hyperconnectivity

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-03

Dopamine replacement therapy (DRT) alleviates motor symptoms in Parkinsons disease (PD) but can trigger hallucinations in a subset of patients, yet the neural basis of this selective vulnerability is unknown. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Structural, Functional and Cognitive Validation of a Deep-Learning MCI-to-AD Conversion Model in OASIS-3

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-10

BackgroundDeep-learning models predict mild cognitive impairment (MCI)-to-Alzheimers disease (AD) conversion from structural MRI with high accuracy. 1 key finding →

Design: longitudinal study Participants: 40 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Vascular and neurodegenerative contributions to cognitive decline and multidomain progression in de novo Parkinsons disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-11

Greater baseline WMH burden was associated with differential longitudinal progression in converters across eleven clinical outcomes, including cognition, gait, and functional independence (all q<0.05). 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clonal Haematopoiesis Tracks Alzheimer's-like Cortical Atrophy in Community-Dwelling Older Adults

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-12

BackgroundClonal haematopoiesis (CH), the age-related expansion of mutated blood stem cells, is detectable in around 10% of people in their seventies, rises steeply with age, and is associated with several diseases. 5 key findings →

Design: longitudinal study Participants: 1,091 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The United States CADASIL Consortium: Baseline Findings from a Natural History Study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-22

Compared with controls, adjusted odds of classification into a more impaired CDR category were higher in all tiers (OR 2.55-5.08, 95% CI 1.22-11.34). 1 key finding →

Design: longitudinal study Participants: 343 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cortical Tau Aggregation Patterns associated with Apraxia in Alzheimer's Disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2024-04-10

We identified significant clusters of tau-aggregation in praxis-related regions (e.g., supramarginal gyrus, angular gyrus, temporal, parietal and occipital regions) that were associated with apraxia. 4 key findings →

Participants: 32 Evidence: low

Full summary, score breakdown and related studies → Original source

Large-scale head-to-head comparison of on- and off-target profiles of [18F]Tauvid and [18F]MK6240 tau-PET in aging and Alzheimer’s disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-11-01

[ 18 F]Tauvid and [ 18 F]MK6240 capture largely overlapping patterns of tau pathology, but differ notably in the magnitude of off-target binding. 3 key findings →

Participants: 681 Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed